



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

30 April 2014
EMA/CAT/315050/2014
Procedure Management and Business Support Division

Committee for Advanced Therapies (CAT)

Minutes of the 15th – 16th April 2014 meeting

Chair: Paula Salmikangas, Vice-chair: Martina Schübler-Lenz

Declaration on conflict of interest

In accordance with the Agency's revised Policy and Procedure on the handling of conflicts of interests, participants in this meeting were asked to declare any conflict of interests on the matters for discussion (in particular any changes, omissions or errors to the already declared interests). No additional conflicts of interest were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Scientific Committee members and, where relevant, experts attending the plenary meeting, as announced by the Scientific Committee Secretariat at the start of meeting. The discussion, deliberations and voting took place in the presence of 22 CAT members (quorum reached).

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regards to therapeutic indications listed against products, it must be noted that these may not reflect the full wording proposed by the applicant and may also vary during the course of the review. The procedures discussed at CAT are on-going and therefore certain aspects are considered confidential. Additional details on some of the procedures (for example the ATMP classification procedure) will be published in the CAT monthly report. For orphan medicinal products the product name and the applicant are published to be consistent with already publicly available information. Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes. Further information with relevant explanatory notes can be found at the end of this document.

Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present following a request for access to documents under Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



1. PLENARY RELATED DOCUMENTS

1.1. AGENDA (EMA/CAT/58386/2014) and **TIMESCHEDULE** (EMA/CAT/176831/2014) for the CAT plenary to be held on 15th and 16th April 2014: **for adoption**

1.2. TABLE OF DECISIONS CAT plenary held on 13th and 14th March 2014 (EMA/CAT/175612/2014): **for information**

1.3. MINUTES of the CAT plenary held on 13th and 14th March 2014 (EMA/CAT/180728/2014): **for adoption**

1.4. PRE-MEETING LIST of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session of 15th – 16th April 2014: **for information**

See April 2014 minutes (to be published post May 2014 CAT meeting)

2. EVALUATION OF ATMPS

2.1. OPINION

No items on the agenda

2.2. ORAL EXPLANATION

No items on the agenda

2.3. LIST OF QUESTIONS

2.3.1. (allogeneic human heterologous liver cells) (EMA/H/C/003750). Therapeutic indication: Treatment of urea cycle disorders.

Rapporteur and CoRapporteur presented the draft list of questions.
The revised list of questions was adopted.

For discussion:

- BWP report
- PRAC's RMP AR (endorsed in April 2014)

For adoption:

- List of Questions

2.4. DAY 80 ASSESSMENT REPORT

No items on the agenda

2.5. RE-EXAMINATION PROCEDURE (NEW APPLICATIONS)+UNDER ARTICLE 9(2) OF REGULATION No 726/2004

No items on the agenda

2.6. WITHDRAWAL OF APPLICATION

No items on the agenda

2.7. ONGOING EVALUATION PROCEDURES

2.7.1. H0002736 (human autologous spheroids of matrix-associated chondrocytes for transplantation). Proposed therapeutic indication: treatment of isolated acute and chronic chondral or osteochondral articular cartilage defects of traumatic genesis or unknown etiology (e.g. osteochondritis dissecans). The medicinal product is applicable for defect sizes up to 10 cm² (International Cartilage Repair Society [ICRS] grade III or IV). Treatment is eligible for single as well as multiple adjacent defects. Cartilage defects of the knee, hip, elbow, shoulder and ankle joints were treated successfully. In a few cases, defect sizes between 11 and 23 cm² were treated successfully. The product is indicated for adults and adolescents with a closed epiphyseal growth plate

For information:

- Letter and attachment from applicant dated 31st March 2014

For discussion:

- Agreement to consult the Biostatistics WP
 - Draft Question to the Biostatistics WP
-

CAT noted the letter from the applicant.

CAT decided that there is no need to consult the Biostatistic working party.

2.8. NEW APPLICATIONS

No items on the agenda

2.9. GMP and GCP INSPECTIONS REQUESTS

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.10. POST-AUTHORISATION

2.10.1. Type II Variations

No items on the agenda

2.10.2. Other PA Activities

2.10.2.1. ChondroCelect (characterised viable autologous cartilage cells expanded *ex vivo* expressing specific marker proteins) MAH: TiGenix N.V. (EMA/H/C/00878/016)

Scope: Randomised control trial protocol TIG/ACT/04/2009

For adoption:

- List of Questions to Healthcare Professional Organisations (HCPOs)

CAT Rapporteur: E. Flory (DE)
CAT Co-rapporteur: O. Tenhunen (FI)
CHMP Co-ordinator: J. Müller-Berghaus (DE)

CAT adopted the list of questions to be sent to the HCPOs. CAT agreed with the response timeline and the organisations to be consulted.

2.10.2.2. ChondroCelect (characterised viable autologous cartilage cells expanded *ex vivo* expressing specific marker proteins) MAH: TiGenix N.V. (EMA/H/C/00878/018)

Scope: Non-interventional registry on the use of ChondroCelect to document the clinical effectiveness and safety outcome of treatment with ChondroCelect in real life in a patient population within the authorised indication

For adoption:

- List of Questions to Healthcare Professional Organisations (HCPOs)

CAT Rapporteur: E. Flory (DE)
CAT Co-rapporteur: O. Tenhunen (FI)
CHMP Co-ordinator: J. Müller-Berghaus (DE)

See 2.10.2.1.

2.10.2.3. Glybera (EMA/H/C/002145) MAH: UniQure Biopharma B.V. *Orphan*

For information:

- Report from the rapporteur

CAT Rapporteur: E. French/J. McBlane (UK)
CHMP Co-ordinator: G. Markey (UK)

Following additional information relevant to this issue will be provided to CAT members via Eudralink:

- CHMP AR (July 2012) – initial MAA
- Background information

CAT agreed with following timetable:

3. CERTIFICATION

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4. SCIENTIFIC RECOMMENDATION ON CLASSIFICATION OF ATMPs

<p>4.1. MBM Cell [Nuclear fraction separated from autologous bone marrow aspirate]. Proposed indication: stage I-III of osteoarthritis and osteochondral lesion</p> <p>For information:</p> <ul style="list-style-type: none">▪ ATMP Classification report	<p>The European Commission raised no comments.</p> <p>The information was noted.</p>
<p>4.2. [allogeneic genetically engineered TCR-/CD52-/RQR8+/CD19 CAR+ T cells]. Proposed indication: CD19+ B-cell lymphomas</p> <p>For information:</p> <ul style="list-style-type: none">▪ ATMP Classification report	<p>The European Commission raised no comments.</p> <p>The information was noted.</p>
<p>4.3. [characterised viable autologous stem cells expanded in vitro]. Proposed indication: treatment of degenerative arthritis, osteoarthritis (OA), articular cartilage defects in the knee, ankle or hip joints.</p> <p>For discussion:</p> <ul style="list-style-type: none">▪ Response to the List of Issues received on 19th March 2014 <p>For adoption:</p> <ul style="list-style-type: none">▪ ATMP Classification report	<p>See also 7.3.</p> <p>The CAT adopted by consensus the draft scientific recommendations. This product is classified as a .</p> <p>CAT secretariat to send the draft scientific recommendation to the Commission for comments until 2 May 2014</p> <p>The CAT recommendation will be considered final if no comments are received from the Commission. The final report will be sent thereafter to the Applicant.</p>
<p>4.4. [autologous collagen type II-specific regulatory Treg lymphocyte expanded population]. Proposed indication: treatment of inflammatory eyes diseases and inflammatory articular diseases</p> <p>For adoption:</p> <ul style="list-style-type: none">▪ ATMP Classification report	<p>The CAT adopted by consensus the draft scientific recommendations. This product is classified as a .</p> <p>CAT secretariat to send the draft scientific recommendation to the Commission for comments until 2 May 2014</p> <p>The CAT recommendation will be considered final if no comments are received from the Commission. The final report will be sent thereafter to the Applicant.</p>

4.5. [polyethylene terephthalate (PET) scaffold seeded with autologous bone marrow derived mononuclear cell]. Proposed indication: reconstruction of trachea subsequent to damage or stenosis due to cancer, injury or infection.

For adoption:

- ATMP Classification report

An ITF Briefing meeting took place in November 2013. The CAT adopted by consensus the draft scientific recommendations. This product is classified as a .

CAT secretariat to send the draft scientific recommendation to the Commission for comments until 2 May 2014

The CAT recommendation will be considered final if no comments are received from the Commission. The final report will be sent thereafter to the Applicant.

CAT discussed on the best way to retrieve information from previous ATMP classifications (to help them when preparing the ATMP classification reports). CAT members were asked to inform the CAT secretariat what fields should be included in the Classification excel table (tabled in CAT MMD/General).

4.6. [concentrate of autologous, uncultured, custom prepared bone marrow aspirate]. Proposed indication: field of regenerative medicine: bone damaged by disease (e.g. osteonecrosis), fracture or age-related loss of bone function.

For information:

- Request received on 1st April 2014

For adoption:

- Appointment of CAT Co-ordinator
- Timetable

Nominations were received from:

The following CAT member was appointed as the CAT co-ordinator:

4.7. [an anti-infectious naked DNA vaccine encoding mutation-inactivated E7-E6 fusion protein from Human Papillomavirus 16 linked to the human chemokine hMIP-1 α via a dimerization module derived from human IgG3.]. Proposed indication: to prevent and treat HPV16 induced pre-malignancies and malignancies.

For information:

- Request received on 1st April 2014

For adoption:

- Appointment of CAT Co-ordinator
- Timetable

Nominations were received from:

The following CAT member was appointed as the CAT co-ordinator:

4.8. Reflection paper on classification of ATMPs: **for discussion:**

- Revised reflection paper, draft dated 16 April 2014.

Note: Drafting Group meeting will take place on 15th April from 6.30pm-7.30pm, room 3C

The outcome of the drafting group meeting was presented. CAT members were asked to send written comments by 2 May. The drafting group members will finalise the revision of the reflection paper prior to the May CAT meeting for adoption for external consultation.

5. SCIENTIFIC ADVICE

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

There was a general discussion on the new SAWP-CAT interaction scheme and the level of detail of the report / written contribution by the CAT Rapporteur. A format has not yet been defined (this will be done once more experience has been gained), but it has been clarified that the CAT Rapporteur / CAT do not have to provide feedback on all questions (this remains the responsibility of the SAWP Coordinators). The initial feedback, concerns and issues identified by the CAT will be very useful for the SAWP and will be taken into consideration during their first discussion.

It was mentioned that CAT can also provide initial feedback on the quality questions, especially because of the close link between quality, non-clinical and clinical aspects for ATMPs. These observations can then be provided to both the SAWP and the BWP for their discussion.

6. PRE-AUTHORISATION ACTIVITIES

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric Investigation Plan (PIP)

7. ITF BRIEFING MEETINGS IN THE FIELD OF ATMPs

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

8. ORGANISATIONAL MATTERS

8.1. Regulatory and Procedural Guidance

8.1.1. Legislation on tissues and cells: legislative proposals on importation of tissues and cells and on coding system for each donation: **for discussion**

Initial discussion took place in March 2014
Postponed to May 2014

8.1.2. Report from the European Commission to the European Parliament and the Council on the application of the ATMP Regulation: **for information**

Report published on the EC website on 1st April 2014
Noted

8.1.3. New Agency fee incentives for SMEs for post-authorisation activities. New financial incentives to support micro, small and medium-sized enterprises (SMEs) developing medicines for human and veterinary use came into force on 1 April 2014. The new incentives apply to post-authorisation activities, and include total or partial fee exemptions: **for information**

[Press Release](#)
Noted

8.2. CAT Meeting Organisation

8.2.1. CAT/CHMP/COMP joint informal meeting to be held in Rome on 28th – 30th October 2014 under the auspices of the Italian Presidency of the Council of the European Union
For discussion:

- Topics for the agenda

8.2.2. CAT/PDCO joint informal meeting hosted by the Heads of the Italian and Slovenian NCAs in November 2013

- **For adoption:**
 - Draft minutes

8.2.3. CAT meetings dates for 2015, 2016, 2017 and 2018: **for adoption**

Adopted

8.2.4. 2014 initial MAAs submission planning update: **for information**

CAT noted the information. No comments were raised.

-
- 8.2.5.** CAT-Meeting Management Documents (MMD)
For information:
- MMD useful tips for delegates
 - Streamlined architecture
-

CAT noted the MMD useful tips document and the new MMD architecture.

This agenda item will be brought back to the May CAT meeting.

8.3. Co-ordination with Committees/WPs/SAGs

- 8.3.1.** CHMP March 2014 ToD: **for information**

Noted

- 8.3.2.** COMP April 2014 agenda: **for information**

Noted

8.4. CAT's Work Programme

- 8.4.1.** Objectives 2014-2015
For agreement on objectives for 2014:

Postponed until May meeting

- Appointment of Organising/programme committee members for:
 - 2) Assessor training
 - 3) Interested parties meeting
 - Discussion of scientific topics identified for horizon scanning
 - Appointment of CAT member(s) to analysis and review of existing guidelines
-

- 8.4.2.** Joint CAT-DGTI workshop (11 September 2014).

- For information:**
- feedback from the telecon of the Organising Committee (20 March 2014)

Organising committee for a joint CAT-DGTI workshop:

CAT agreed with the draft programme and the identified CAT speakers for the different topics.

- For discussion:**
- Draft Programme
 - Workshop flyer
-

9. CAT's DGs / PCWP and HCPWP

9.1. DG on GTMP Guidelines

9.2. DG on CTMP and TEP Guidelines

- 9.2.1.** CAT workshop on Cell based therapies for Cardiac Repair scheduled for 14th-15th May 2014

For discussion:

- Draft agenda
- CAT attendance.

Moderators:

A preparatory meeting will take place from 1pm – 2.30pm on Tuesday 15th April 2014, room 3C

CAT members interested to attend this workshop should inform the CAT secretariat not later than 2 May 2014, indicating if they plan to attend the sessions on Wednesday afternoon (from 14.00 to 18.00), Thursday morning (from 9.00 to 11.00) or both.

Note that the layout of the room does not allow the participants to enter or leave the room without disrupting the discussions or presentations: participants are therefore requested to attend the entire workshop session.

CAT agreed with the agenda of the workshop.

10. OTHER SCIENTIFIC TOPICS

- 10.1.** European Clinical Trials Framework. Regulation of the EP and the Council on clinical trials on medicinal products for human use and transparency initiatives

For information:

- Presentation on the published document

A presentation on the new clinical trial Regulation; which was adopted by the EU in December 2013, was given to the CAT.

- 10.2.** Regulators Forum Cell Therapy discussion group (RFCTDG)

For information:

- Feedback from the telecon of 25th March 2014
- Agenda of the telecon of 25th March 2014
- Agenda of the APEC cell and tissue-based Therapeutic Products Workshop (1st-3rd July 2014)

For agreement:

- CAT participation to the APEC meeting and the in-person meeting of RFCTDG (Singapore; 3rd July 2014; adjacent to the APEC Workshop); proposal for CAT chair to attend

Feedback from the telecon of 25 March will be given at the May CAT meeting.

CAT agreed for P Salmikangas to participate on behalf of CAT to the APEC cell and tissue based workshop (1-3 July 2014) and the adjacent in-person RFCTDG meeting on 3 July 2014.

<p>10.3. Regulation Forum Gene Therapy discussion Group (RFGTDG) For information:</p> <ul style="list-style-type: none"> ▪ Next international telecon will take place on 30th April (agenda not yet available) 	<p>Noted. The agenda will be included in the CAT MMD as soon as it becomes available.</p>
<p>10.4. International Standardization Organisation and Identification of Medicinal Products. (ISO/IDMP EU). Re-activation and extension of a task force to develop the technical specifications describing implementation guides of data elements & structures. Call for nomination for core members</p>	<p>CAT members willing to contribute to this activity should inform the CAT secretariat by 30 April 2014.</p>
<p>10.5. The Committee on Bioethics (DH-BIO) of the Council of Europe's. For review by the CAT:</p> <ul style="list-style-type: none"> ▪ Working document: '<i>Working document on research on biological materials of human origin</i>' 	<p>The DH-BIO is particularly interested in receiving comments on the following issues:</p> <ul style="list-style-type: none"> ▪ Storage for future research of residual biological materials (Article 13) ▪ Removal storage and use of biological materials from persons not able to consent (articles 12,14 and 17, paragraph 4) ▪ Governance (Articles 20-24)
<p>Postponed until May CAT meeting</p>	
<p>11.A.O.B.</p>	
<p>11.1. Project 2014: move to 30, Churchill Place, Canary Wharf For information:</p> <ul style="list-style-type: none"> ▪ Update presentation 	<p>CAT noted the information provided.</p>

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CAT agenda and should be read in conjunction with the agenda or the minutes.


Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (*section 2.9*) and Post-authorisation activities (*section 2.10*).

New applications (sections 2.1 to 2.9)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (*section 2.3*) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.5)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.6)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.8)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Inspections Issues (section 2.9)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.10)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

ATMP Certification (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

Pre-Authorisation (section 6)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs (Section 7)

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

Organisational matters (section 8)

This section includes topics related to Regulatory and Procedural Guidance, CAT meeting organisation (including CAT membership) and Co-ordination with other Committees, Working Parties, Scientific Advisory Groups and other groups.

CAT's DGs / PCWP and HCPWP (section 9)

This section refers to the activities of the CAT drafting groups developing Scientific Guidelines for gene therapy medicinal products and for cell-based medicinal products, the EMA/CAT-Notified Body Collaboration Group, the Patient and Consumer Working Party (PCWP) and the Healthcare Professionals Working Party (HCPWP).

Other Scientific Topics (section 10)

This section includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

List of participants: ***including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 15-16 April 2014 meeting.***

CAT Member	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/substance
Paula Salmikangas	CAT chair	Full involvement	
Ilona G. Reischl	Austria	Full involvement	
Claire Beuneu	Belgium	Full involvement	
Rozalina Kulaksazova	Bulgaria	Full involvement	
Ivana Haunerova	Czech Republic	Full involvement	
Sinan B. Sarac	Denmark	No restrictions	
Toivo Maimets	Estonia	Full involvement	
Nicolas Ferry	France	Full involvement	
Martina Schüssler-Lenz	Germany	Full involvement	
Zsuzsanna Buzás	Hungary	Full involvement	
Maura O'Donovan	Ireland	Full involvement	
Paolo Gasparini	Italy	Full involvement	
Romaldas Mačiulaitis	Lithuania	No restrictions	
Johannes H. Ovelgönne	Netherlands	Full involvement	
Marit Hystad	Norway	Full involvement	
Dariusz Śladowski	Poland	No restrictions	
Simona Badoi	Romania	Full involvement	
Mikuláš Hrubíško	Slovakia	No restrictions	
Metoda Lipnik-Stangelj	Slovenia	Full involvement	
Sol Ruíz	Spain	Full involvement	
Lennart Åkerblom	Sweden	Full involvement	
Bernd Gänsbacher	IEOT	Full involvement	
Kieran Breen	EPDA	No restrictions	

CAT Alternate	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/ substance
Ivica Malnar	Croatia	No restrictions	
Sophie Lucas	France	Full involvement	
Egbert Flory	Germany	Full involvement	
Anthony Samuel	Malta	Full involvement	
Rune Kjeklen	Norway	No restrictions	
Margarida Menezes-Ferreira	Portugal	Full involvement	
Marcos Timón	Spain	Full involvement	
James McBlane	UK	Full involvement	
Esteve Trias-Adroher	EATB	Full involvement	

CAT members and alternates by phone	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/ substance
Olli Tenhunen	Finland	Full involvement	
Monique Wakelkamp	Sweden	Full involvement	

CAT Expert	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/ substance
Guido Panté	Italy	No restrictions	Entire meeting
Wiebke Hoppensack	Germany	No restrictions	Entire meeting
Susana Rojo	Spain	No restrictions	Entire meeting